Table 4.
Univariate and multivariate analysis of OS.
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age (≥60/<60) | 0.845 | 0.419-1.704 | 0.638 | |||
| Sex (male/female) | 1.335 | 0.664-2.683 | 0.418 | |||
| BMI | ||||||
| 18.5-24 | Ref. | |||||
| <18.5 | 5.349 | 0.684-41.806 | 0.110 | |||
| >24 | 0.966 | 0.420-2.222 | 0.934 | |||
| History of HBV infection (Yes/No) | 0.751 | 0.360-1.568 | 0.446 | |||
| KPS | 0.944 | 0.897-0.994 | 0.030 | 0.946 | 1.405-8.886 | 0.088 |
| CEA (≥5/<5) | 1.224 | 0.542-2.768 | 0.627 | |||
| CA19-9 (≥34/<34) | 2.172 | 1.018-4.637 | 0.045 | 2.493 | 0.988-6.294 | 0.053 |
| ALB (≥35/<35) | 0.788 | 0.275-2.264 | 0.658 | |||
| LDH (≥214/<214) | 1.707 | 0.820-3.556 | 0.153 | |||
| TBil (≥21/<21) | 4.302 | 1.600-11.569 | 0.004 | 1.265 | 0.229-6.984 | 0.787 |
| Child-Pugh stage (B/A) | 2.214 | 0.522-9.385 | 0.281 | |||
| Histological type (Other types/Adenocarcinoma) | 1.020 | 0.241-4.324 | 0.978 | |||
| Differentiation (Poor/Well+Medium) | 3.079 | 1.429-6.353 | 0.002 | 3.534 | 1.405-8.886 | 0.007 |
| Ki67 | 1.009 | 0.994-1.025 | 0.246 | |||
| Tumor number (Multiple/Single) | 2.557 | 1.090-5.999 | 0.031 | 2.091 | 0.768-5.688 | 0.149 |
| Timor site | ||||||
| Intrahepatic | Ref. | |||||
| Perihilar | 1.457 | 0.436-4.866 | 0.541 | |||
| Distal | 1.357 | 0.316-5.835 | 0.681 | |||
| Largest tumor diameter | 0.973 | 0.875-1.082 | 0.616 | |||
| Macrovascular invasion (Yes/No) | 0.894 | 0.268-2.979 | 0.855 | |||
| Local lymph node metastasis (Yes/No) | 1.006 | 0.495-2.048 | 0.986 | |||
| Liver metastasis (Yes/No) | 1.162 | 0.554-2.437 | 0.692 | |||
| FIB-4 (≥3.29/<3.29) | 2.686 | 1.147-6.287 | 0.023 | 3.219 | 1.112-9.319 | 0.031 |
| SII (≥1165.96/<1165.96) | 3.505 | 1.505-8.167 | 0.004 | 3.501 | 0.825-14.849 | 0.089 |
| NLR (≥6.04/<6.04) | 2.001 | 0.810-4.945 | 0.133 | |||
| PLR (≥296.72/<296.72) | 2.739 | 1.084-6.923 | 0.033 | 1.005 | 0.298-3.389 | 0.994 |
| PNI (≥43.60/<43.60) | 0.382 | 0.183-0.800 | 0.011 | 0.592 | 0.205-1.707 | 0.332 |
| Total course of immunotherapy | 0.939 | 0.866-1.018 | 0.126 | |||
P-value < 0.05 is statistically significant.
OS, overall survival; HR, hazard ratio; CI, confidence interval; Ref, reference; BMI, body mass index; HBV, hepatitis B virus; KPS, Karnofsky performance status score; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; ALB, albumin; LDH, lactate dehydrogenase; Tbil, total bilirubin; FIB-4, the fibrosis-4 index; SII, systemic immune-inflammation index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index.